Pfizer Inc. (PFE) has withdrawn an application seeking U.S. regulatory approval to market its antidepressant Pristiq as a treatment for certain menopause-related symptoms in women.
The U.S. Food and Drug Administration in September declined to approve Pfizer's bid to expand the drug's uses to include relief of moderate-to-severe vasomotor symptoms associated with menopause, such as hot flashes and night sweats.
via foxbusiness.com
No comments:
Post a Comment